Good morning :)
Place Order
Add to Watchlist

Aarti Drugs Ltd

AARTIDRUGS

Aarti Drugs Ltd

AARTIDRUGS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,799 cr, stock is ranked 855
Moderate RiskStock is 2.13x as volatile as Nifty
416.301.84% (-7.80)
416.301.84% (-7.80)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,799 cr, stock is ranked 855
Moderate RiskStock is 2.13x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹3,799 cr, stock is ranked 855
Moderate RiskStock is 2.13x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
24.892.960.24%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.096.500.52%

Forecast & Ratings

Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Aarti Drugs Limited is a pharmaceutical company offering active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antifungals, antibiotic, antidiabetic, sedative and vitamins.

Investor Presentation

View older 

Jan 29, 2025

PDF
View Older Presentations
PE Ratio
43.84
1Y Return
16.69%
Buy Reco %
85.29
PE Ratio
28.85
1Y Return
2.17%
Buy Reco %
72.73
PE Ratio
66.58
1Y Return
23.00%
Buy Reco %
70.37
PE Ratio
54.32
1Y Return
18.22%
Buy Reco %
80.00
PE Ratio
18.53
1Y Return
0.43%
Buy Reco %
40.63
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 10.08%, vs industry avg of 9.04%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.71% to 0.67%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 13.82%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue1,139.841,199.171,244.681,567.121,812.042,162.572,499.972,718.242,532.612,345.83
Raw Materialssubtract758.16765.89821.921,026.311,210.601,310.661,750.061,863.711,626.102,050.72
Power & Fuel Costsubtract53.9359.4271.4284.39103.8398.20128.34156.10154.31
Employee Costsubtract40.1947.9552.1454.5561.3565.8869.3080.4390.60
Selling & Administrative Expensessubtract37.9241.7447.6054.6680.1698.43104.24104.6695.12
Operating & Other expensessubtract69.8389.6948.68130.1284.63144.28104.11201.71241.61
Depreciation/Amortizationsubtract36.5338.4640.0642.5648.7549.8850.0550.3251.4554.48
Interest & Other Itemssubtract48.0240.0238.3643.5137.4226.2323.9137.1437.8935.84
Taxes & Other Itemssubtract26.5534.2142.2041.2743.8988.6064.9257.8864.1052.12
EPS7.098.518.679.5115.0830.0922.0717.9618.5816.61
DPS1.690.250.250.250.502.501.001.001.001.00
Payout ratio0.240.030.030.030.030.080.050.060.050.06

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Jun 7PDF
May 9PDF
FY 2023

Annual report

PDF

Investor Presentation

May 2PDF
Jan 27PDF
Oct 20PDF
+2 more
FY 2024

Annual report

PDF

Investor Presentation

Jul 21PDF
FY 2025

Annual Report Pending

Investor Presentation

Jan 29PDF
Sep 20PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Aarti Drugs Ltd22.162.960.24%
Sun Pharmaceutical Industries Ltd43.846.260.77%
Cipla Ltd28.854.440.88%
Torrent Pharmaceuticals Ltd66.5816.090.86%

Price Comparison

Compare AARTIDRUGS with any stock or ETF
Compare AARTIDRUGS with any stock or ETF
AARTIDRUGS
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding55.38%7.78%0.99%2.28%33.57%

Mar 2024

Jun 2024

Sep 2024

Dec 2024

Shareholding History

SepDec '23MarJunSepDec '242.33%2.10%2.56%2.96%2.50%2.28%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.53%

Top 5 Mutual Funds holding Aarti Drugs Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
6.0976%1.39%-0.02%26/78 (+1)
1.3625%0.97%0.71%30/50 (+6)
0.9794%1.11%-0.10%24/33 (-3)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

AARTIDRUGS has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.24%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.42 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateFeb 4, 2025

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 4, 2025

Cash Dividend

Ex DateEx DateFeb 6, 2024

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 6, 2024

Cash Dividend

Ex DateEx DateFeb 8, 2023

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 8, 2023

Cash Dividend

Ex DateEx DateFeb 9, 2022

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 9, 2022

Cash Dividend

Ex DateEx DateNov 3, 2020

Interim
Interim | Div/Share: ₹2.50

Dividend/Share

₹2.50

Ex DateEx Date

Nov 3, 2020

News & Opinions
Corporate
Aarti Drugs receives affirmation in credit ratings from ICRA

Aarti Drugs has received reaffirmation in credit rating at ICRA AA-; Stable/ ICRA A1+ for bank facilities aggregating Rs 1452.8 crore. Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Aarti Drugs gains as PAT rises to Rs 37 cr in Q3; declares dividend of Re 1/sh

Revenue from operations declined 6.44% to Rs 568.50 crore in third quarter of FY25 as compared with Rs 607.61 crore posted same period a year ago. Profit before tax shed 1.53% to Rs 50.76 crore in the third quarter of FY25 as against Rs 51.55 crore recorded in the same quarter last year. EBITDA stood at Rs 62.3 crore in Q3 of FY25, down 13% from Rs 71.8 crore posted in the December 2023 quarter. EBITDA Margin to 11.2% in Q3 FY25 as against with 11.8% posted in Q3 FY24. During the quarter, revenue from API segment declined 5.2% YoY to Rs 460 crore, formulation business dropped 39.4% YoY to Rs 48 crore while specialty chemicals increased 7.6% YoY to Rs 33.8 crore and intermediaries & others jumped 46.3% YoY to Rs 14.8 crore while in Q3 FY25. On standalone basis, the company's net profit increased 21.85% to Rs 38.53 crore in Q3 FY25 as compared with Rs 31.62 crore in Q3 FY24. Revenue stood at Rs 525.91 crore in December 2024 quartre, down 2.58% YoY. The standalone business contributed approximately 91% to the consolidated revenue for the quarter. Around 64% of the revenues came from the domestic market and 36% from the exports market for third quarter of FY25 for a standalone business. Within the API business, the antibiotic therapeutic category contributed around 38.6%, anti-diabetic approximately 16.1%, anti-protozoal around 16.5%, anti-inflammatory approximately 11.9%, antifungal around 12% and the rest contributed approximately 5% to total API sales for Q3 FY25. Meanwhile, the company's board has declared an interim dividend of Re 1 per equity share for the financial year 2023-24. The record date for the purpose of payment of interim dividend has been fixed as 4 February 2025. Adhish Patil, CFO & COO, Aarti Drugs, said, 'This quarter has presented significant challenges for our API segment, with both revenue and profit declining on a year-on-year basis. This is mainly due to reduced market prices and weaker demand. Although prices remained stable during the December quarter, there was a negative price variance when compared to the same period last year. Formulation segment revenue stood at Rs. 48.6 crores for the quarter, with an export contribution of 47% whereas in 9M FY25 revenue stood at Rs 186.9 crores. The greenfield project at Sayakha, Gujarat for Speciality Chemicals will commence trial production in this quarter. With this, the operating leverage is expected to kick in from the subsequent quarter with improved capacity utilization. There had been certain teething issues in Tarapur greenfield project, which are sorted now and we expect to ramp up the production to 500+ tonnes per month by the end of March'25. In total we will have sequential ramp up of capacity to 1,600 tonnes per month by end of FY26. During 9M FY25, the company has incurred capex of approximately Rs 136 crore mainly towards capacity expansion, backward integration and new product launches. We anticipate a total capex of around Rs 200 crore for the full year. This capex would we mainly through internal accruals and partly through term loans. Despite facing these short-term challenges, we are staying focused on our long-term goals. We are confident about achieving double digit growth in revenues with EBITDA Margins of 13%-14% in FY26 which is a healthy indicator of our financial stability and operational efficiency. Despite API pricing pressures, driven by fluctuating raw material costs, heightened competition, and regulatory demands in global markets we remain committed to achieving growth and profitability by enhancing operational efficiencies and expanding our market presence. We are dedicated to tackling these challenges and emerging stronger in the future.' Aarti Drugs forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Speciality Chemicals and produces Formulations with its whollyowned subsidiary-Pinnacle Life Science Private. Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Aarti Drugs fixes record date for interim dividend

Aarti Drugs has fixed 04 February 2025 as record date for purpose of interim dividend of Re 1 per equity share of Rs 10 each for FY 2024-25. Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Aarti Drugs consolidated net profit rises 1.04% in the December 2024 quarter

Net profit of Aarti Drugs rose 1.04% to Rs 37.05 crore in the quarter ended December 2024 as against Rs 36.67 crore during the previous quarter ended December 2023. Sales declined 8.14% to Rs 556.60 crore in the quarter ended December 2024 as against Rs 605.94 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales556.60605.94 -8 OPM %11.0911.58 - PBDT64.5564.21 1 PBT50.7551.55 -2 NP37.0536.67 1 Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Aarti Drugs standalone net profit rises 21.85% in the December 2024 quarter

Net profit of Aarti Drugs rose 21.85% to Rs 38.53 crore in the quarter ended December 2024 as against Rs 31.62 crore during the previous quarter ended December 2023. Sales declined 4.40% to Rs 514.54 crore in the quarter ended December 2024 as against Rs 538.21 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales514.54538.21 -4 OPM %11.7111.10 - PBDT64.0554.67 17 PBT52.0342.87 21 NP38.5331.62 22 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Board of Aarti Drugs recommends Interim Dividend

Aarti Drugs announced that the Board of Directors of the Company at its meeting held on 29 January 2025, has recommended a Interim dividend of Rs.1 per share (i.e.10%), subject to the approval of the shareholders.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Aarti Drugs to conduct board meeting

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 29 January 2025.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Spotlight
Aarti Drugs sizzles after Tarapur facility gets EIR from USFDA

USFDA has determined that the inspection classification of this facility is voluntary action indicated (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP). Due to this company can export the products such as Ciprofloxacin HCl API, Zolpidem Tartrate API, Raloxifene HCl API, Celecoxib API and Niacin API in US Market. USFDA had inspected the company's API manufacturing facility at Plot No-E-22, MIDC, Tarapur, Maharashtra from 12th to 20th September 2024. Aarti Drugs is primarily involved in manufacturing and marketing of Active Pharmaceutical Ingredients (API), Pharma Intermediates and Specialty Chemicals. The company's consolidated net profit dropped 11.6% to Rs 35.01 crore on 6.7% decline in net sales to Rs 598.33 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Aarti Drugs's receives Establishment Inspection Report for API manufacturing unit

Aarti Drugs has received Establishment Inspection Report (EIR) from USFDA concluding the inspection as closed for its API manufacturing facility located at Plot No-E-22, MIDC, Tarapur, Maharashtra. UFDA has determined that the inspection classification of this facility is 'voluntary action indicated' (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP). Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Aarti Drugs consolidated net profit declines 11.57% in the September 2024 quarter

Net profit of Aarti Drugs declined 11.57% to Rs 35.01 crore in the quarter ended September 2024 as against Rs 39.59 crore during the previous quarter ended September 2023. Sales declined 6.74% to Rs 598.33 crore in the quarter ended September 2024 as against Rs 641.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales598.33641.54 -7 OPM %11.2111.92 - PBDT59.6068.88 -13 PBT45.8856.27 -18 NP35.0139.59 -12 Powered by Capital Market - Live

3 months agoCapital Market - Live